Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Clarence B. Vaughn"'
Autor:
Jacob D. Bitran, Clarence B. Vaughn, Gary S. Lazar, Gabriel N. Hortobagyi, Aman U. Buzdar, Silvana Martino, Gary Spitzer, Charles E. Vogel, Robert W. Dubois, Stephen E. Jones, Sandra M. Swain, Robert Peter Gale, Rolla Edward Park
Publikováno v:
Clinical Transplantation. 14:32-41
BACKGROUND There is controversy whether high-dose chemotherapy and a blood cell or bone marrow autotransplant is a better treatment than conventional-dose chemotherapy for women with local/regional or metastatic breast cancer. Subject selection and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cdeb66144097ffead25d93656475fab9
https://doi.org/10.1034/j.1399-0012.2000.140107.x
https://doi.org/10.1034/j.1399-0012.2000.140107.x
Autor:
Saul E. Rivkin, C. Kent Osborne, John J. Costanzi, J. W. Athens, Danika Lew, Clarence B. Vaughn, Stephanie J. Green, Silvana Martino
Publikováno v:
Cancer. 97(1)
BACKGROUND Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil plus vincristine and prednisone (CMFVP) was compared with single-agent L-phenylalanine mustard (L-PAM) for the treatment of patients with axillary ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d5bd7b848adefd39aff8c9777195e87
https://pubmed.ncbi.nlm.nih.gov/12491501
https://pubmed.ncbi.nlm.nih.gov/12491501
Publikováno v:
Investigational new drugs. 8(1)
Esorubicin (4' deoxydoxorubicin) is a new analogue of the anthracycline, doxorubicin. This compound lacks the hydroxyl group at 4' position on the amino sugar of the anthracycline. Phase II study was designed to determine the clinical response rate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e87e53f3eff74b0aaebbab463d5381
https://pubmed.ncbi.nlm.nih.gov/2188929
https://pubmed.ncbi.nlm.nih.gov/2188929
Autor:
Clarence B. Vaughn, Edward J. Treisman, Barry R. Herschman, Gayle Groshko, Janet Chapman, Pauline L. Nirenberg, Michael J. Bonczak
Publikováno v:
Medical and pediatric oncology. 18(1)
Five to ten percent of patients with adenocarcinoma of the endometrium present with advanced disease [1] or develop metastasis and require systemic therapy for control of disease. About one-third (33%) of recurrent or advanced endometrial cancer resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765c406a658b4155530628834a8bde51
https://pubmed.ncbi.nlm.nih.gov/2294393
https://pubmed.ncbi.nlm.nih.gov/2294393
Autor:
Ben Lin Hom, Robert Chapman, Joel G. Lucas, Harry E. Hynes, John Crowley, Clarence B. Vaughn, Robert B. Livingston
Publikováno v:
Investigational New Drugs. 11:91-92
This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 mont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd2d4bc8d27812813899101bf3504310
https://doi.org/10.1007/bf00873920
https://doi.org/10.1007/bf00873920
Autor:
A. Kennedy, B. Hoogstraten, Clarence B. Vaughn, Tranum Bl, Henry E. Wilson, W. G. Tucker, Frank E. Smith, John H. Costanzi, Tate Thigpen, T. R. Maloney, Bohumil A. Samal, Robert L. Palmer, Saul E. Rivkin
Publikováno v:
Cancer. 41:2078-2083
Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1, plus 5-FU day 1 and 8, and cyclophosphamide day 1 (AFC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ac3cb4aa9ff298853f742e04b1a6098
https://doi.org/10.1002/1097-0142(197806)41:6<2078::aid-cncr2820410602>3.0.co
https://doi.org/10.1002/1097-0142(197806)41:6<2078::aid-cncr2820410602>3.0.co
Autor:
Ronald L. Stephens, Stanley P. Balcerzak, Jess Frank, Robert M. O'Bryan, Clarence B. Vaughn, Howard S. Levin, J. J. Costanzi, Montague Lane, Charles A. Coltman
Publikováno v:
Cancer. 53:406-410
Over a 24-month period, the Southwest Oncology Group (SWOG) conducted a randomized prospective chemotherapeutic trial in 158 patients with advanced prostatic cancer. Patients were initially randomized to receive either a combination of Adriamycin and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b34241768178afffb260ec00af7cfcc7
https://doi.org/10.1002/1097-0142(19840201)53:3<406::aid-cncr2820530307>3.0.co
https://doi.org/10.1002/1097-0142(19840201)53:3<406::aid-cncr2820530307>3.0.co
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 43:387-393
The patterns of radioactive estrogen metabolites in the plasma of patients with a variety of malignancies were determined after the injection of physiological amounts of 17β-estradiol-6,7-3H or of estrone-6,7-3H. The metabolites were separated and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eaf545b1eee56ab4269fb39e21b2b40
https://doi.org/10.1210/jcem-43-2-387
https://doi.org/10.1210/jcem-43-2-387
Autor:
Thomas R. Maloney, Mary A. Foulkes, William S. Fletcher, Barth Hoogstraten, J. J. Costanzi, Nazli Gad-el-Mawla, Clarence B. Vaughn, Bill L. Tranum, J. W. Athens
Publikováno v:
Cancer. 54:2248-2256
The Southwest Oncology Group has completed a study of 213 women with the first recurrence of breast cancer. Eligibility included a radical or modified radical mastectomy for cure and recurrence which had received no other form of therapy. Patients we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68eb3932641abd66b821325e9c5e984f
https://doi.org/10.1002/1097-0142(19841115)54:10<2248::aid-cncr2820541031>3.0.co
https://doi.org/10.1002/1097-0142(19841115)54:10<2248::aid-cncr2820541031>3.0.co
Autor:
J. Benjamin Green, Stephanie Green, P. N. Grozea, Robert M. O'Bryan, Clarence B. Vaughn, Noboru Oishi, William S. Fletcher, Melvin L. Reed, Barbara Metch
Publikováno v:
Medical and Pediatric Oncology. 16:312-319
One hundred twenty-two patients with advanced adenocarcinoma of the breast were randomized to receive adriamycin (AD) alone or a combination of VP-16 plus lower dose adriamycin (VAD). The patients were stratified to good and poor risk. The starting d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d12542ad52140ef0e8b681c066076089
https://doi.org/10.1002/mpo.2950160505
https://doi.org/10.1002/mpo.2950160505